<DOC>
	<DOCNO>NCT01971593</DOCNO>
	<brief_summary>Hypothesis : By block aldosterone signal patient Tetralogy Fallot , Transposition great vessel prior atrial switch , single ventricle `` Fontan '' patient , incident heart failure delay , symptom heart failure ameliorate , risk arrhythmia decrease decrease myocardial fibrosis . Half enrol patient complete SF-36 quality life questionnaire , perform 6 minute walk , blood drawn biomarker analysis enrollment , 3 month without therapy , 6 month therapy , finally 12 month eplerenone therapy . Half enrol patient 3 month drug free period end 12 month therapy . Patients randomly assign drug free period front versus conclusion trial period . Eplerenone start dose 25mg titrate 50mg 4 week tolerate . Blood drawn basic metabolic panel analysis enrollment , 3 month , 4 month allow dose titration , 6 12 month monitoring .</brief_summary>
	<brief_title>The Effects Eplerenone Markers Myocardial Fibrosis Adult Congenital Heart Disease</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Tetralogy Fallot</mesh_term>
	<mesh_term>Transposition Great Vessels</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Established diagnosis tetralogy Fallot , transposition great vessel systemic right ventricle , Fontan type palliation Patient follow regularly Washington Universityaffiliated institution If female , willing use 2 form contraception include one barrier method protocol GFR &lt; 30 ml/min Potassium &gt; 5.0 mmol/L Unable unwilling comply study protocol Use potassium spar diuretic Use aldosterone blocker currently previously Known intolerance eplerenone aldosterone blockade Pregnant , breastfeeding , actively try get pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>